For SOPHiA GENETICS's AI-powered radiomics solution, should we prioritize increasing the number of supported imaging modalities or improving accuracy for existing ones?

Introduction

The trade-off we're examining today is whether SOPHiA GENETICS should prioritize increasing the number of supported imaging modalities or improving accuracy for existing ones in their AI-powered radiomics solution. This decision is crucial for the product's growth and market positioning. I'll analyze this trade-off by considering user needs, technical feasibility, market dynamics, and business impact. Let's dive into the key aspects to make an informed recommendation.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm assuming SOPHiA GENETICS is a leader in AI-driven healthcare solutions. Could you confirm our current market position and main competitors in the radiomics space?

Why it matters: Helps frame the decision in the competitive landscape Expected answer: Top 3 player with 1-2 main competitors Impact on approach: Would influence whether we prioritize differentiation or catching up

• Business Context: Based on our business model, I'm thinking this decision could significantly impact our revenue streams. How does our radiomics solution currently contribute to our overall revenue, and what growth targets are we aiming for?

Why it matters: Aligns product strategy with financial goals Expected answer: 20-30% of revenue, aiming for 50% growth Impact on approach: Higher growth targets might favor expanding modalities

• User Impact: Considering our user base, I'm curious about the distribution of healthcare providers using different imaging modalities. What percentage of our users are requesting support for new modalities versus improved accuracy in existing ones?

Why it matters: Ensures we're addressing the most pressing user needs Expected answer: 60% satisfied with current modalities, 40% requesting new ones Impact on approach: Would help balance improvements vs. expansion

• Technical Feasibility: Looking at our AI capabilities, I'm wondering about the relative complexity of adding new modalities versus improving existing ones. Could you share insights on the technical challenges and resource requirements for each path?

Why it matters: Assesses the feasibility and resource allocation needed Expected answer: New modalities require significant R&D, accuracy improvements are incremental Impact on approach: Might favor accuracy improvements if new modalities are substantially more complex

• Timeline: Considering our product roadmap, I'm thinking about how this decision aligns with our upcoming releases. What's our target timeline for implementing either of these options, and are there any critical market events or regulatory deadlines we need to consider?

Why it matters: Ensures alignment with broader product strategy and market timing Expected answer: 6-12 months for significant improvements, regulatory approval needed for new modalities Impact on approach: Shorter timelines might favor improving existing modalities